HIV Single Therapy PRO 140 Will Enable CytoDyn Inc. (CYDY) to “Take Off” Very Soon, President and CEO Says
Positive results in the PRO 140 clinical trials should mean good news for investors, CytoDyn President Nader Pourhassan said in an interview CytoDyn is currently undervalued but the effectiveness and practical appeal of PRO 140 should contribute to a turning point in stock prices PRO 140, a single agent therapy, is proving highly effective in the treatment of HIV; CytoDyn also planning an expansion of clinical trials to certain types of cancer The growth potential of CytoDyn Inc. (OTCQB: CYDY) is huge, company President and CEO Dr. Nader Pourhassan said in an interview with The Wall Street Transcript (http://ibn.fm/KWCIK). According to…